Monthly Archives: July 2017

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease worldwide and is an increasing cause of liver-related morbidity and mortality. Nonalcoholic steatohepatitis (NASH), the progressive histological subtype of the… Continue reading →

Training fellows to perform endoscopy is challenging. Most trainers genuinely desire to be good teachers, but competing demands can be difficult to navigate. As we consider the hypothetical example below, think about what you might do differently. Continue reading →

Esophageal squamous cell carcinoma (ESCC) is a common malignancy without effective therapy. The exomes of more than 600 ESCCs have been sequenced in the last 4 years, and numerous key aberrations have been identified1-4. Recently, researchers reported … Continue reading →

Eosinophilic esophagitis (EoE) is an emerging disease that is distinguished from gastroesophageal reflux disease (GERD) by the expression of a unique esophageal transcriptome and the interplay of early life environmental factors with distinct genetic s… Continue reading →

Gastroparesis is a complication of diabetes with few treatment options. Relamorelin (also called RM-131) is a selective, prokinetic agonist of ghrelin. We aimed to evaluate efficacy of relamorelin on symptoms and gastric emptying (GE) in a 12-week, pha… Continue reading →

Colorectal cancer (CRC) screening using quantitative fecal immunochemical tests (FITs) is rapidly gaining ground worldwide. FITs are invariably used in a dichotomous manner using pre-specified cut-off values. To optimize FIT-based screening programs, w… Continue reading →

Eosinophilic esophagitis (EoE) is a new disease. It is caused by a T-helper 2 cell response to food antigens in contact with the esophageal mucosa. Although no single feature defines EoE, a constellation of compatible demographic, clinical, endoscopic,… Continue reading →

Although tumor necrosis factor (TNF) antagonists reduce many clinical features of inflammatory bowel disease (IBD), complete mucosal healing occurs in less than 50% of patients. The Fc region of monoclonal antibodies against TNF has immunosuppressive p… Continue reading →

Eosinophilic esophagitis (EoE) is a new disease. It is caused by a T-helper 2 cell response to food antigens in contact with the esophageal mucosa. Although no single feature defines EoE, a constellation of compatible demographic, clinical, endoscopic,… Continue reading →

Although tumor necrosis factor (TNF) antagonists reduce many clinical features of inflammatory bowel disease (IBD), complete mucosal healing occurs in less than 50% of patients. The Fc region of monoclonal antibodies against TNF has immunosuppressive p… Continue reading →